Mutations in KEAP1 lead to uncontrolled activation of NRFE2L2, which targets genes involved in xenobiotic biotransformation reactions and antioxidant metabolism, thereby protecting tumour cells from the effects of cytotoxic chemotherapy [40]. The gene discussed is KEAP1; the disease is neoplasm.